Arbutus to Present at UBS Virtual Global Healthcare Conference
May 12 2020 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company focused on developing a cure for people
with chronic hepatitis B virus (HBV) infection, today announced
that William Collier, Arbutus’ President and Chief Executive
Officer, will present at the UBS Virtual Global Healthcare
Conference on Tuesday, May 19, 2020 at 11:40 AM ET.
A live webcast of the presentation can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com or directly at Live Webcast. An archived replay
of the webcast will be available on the Company’s website after the
conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for people with
chronic hepatitis B virus (HBV) infection. The Company is
advancing multiple drug product candidates that may be combined
into a potentially curative regimen for chronic HBV infection. For
more information, visit www.arbutusbio.com.
Contact Information
Investors and MediaWilliam H. CollierPresident
and CEOPhone: 604-419-3200Email: ir@arbutusbio.com
Pam MurphyInvestor Relations ConsultantPhone: 604-419-3200Email:
ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024